Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method

Chad J. Roy, Alida Ault, Satheesh K. Sivasubramani, J. Patrick Gorres, Chih Jen Wei, Hanne Andersen, Jason Gall, Mario Roederer, Srinivas S. Rao

Research output: Contribution to journalArticlepeer-review

Abstract

Conventional parenteral injection of vaccines is limited in its ability to induce locally-produced immune responses in the respiratory tract, and has logistical disadvantages in widespread vaccine administration. Recent studies suggest that intranasal delivery or vaccination in the respiratory tract with recombinant viral vectors can enhance immunogenicity and protection against respiratory diseases such as influenza and tuberculosis, and can offer more broad-based generalized protection by eliciting durable mucosal immune responses. Controlled aerosolization is a method to minimize vaccine particle size and ensure delivery to the lower respiratory tract. Here, we characterize the dynamics of aerosolization and show the effects of vaccine concentration on particle size, vector viability, and the actual delivered dose of an aerosolized adenoviral vector. In addition, we demonstrate that aerosol delivery of a recombinant adenoviral vaccine encoding H1N1 hemagglutinin is immunogenic and protects ferrets against homologous viral challenge. Overall, aerosol delivery offers comparable protection to intramuscular injection, and represents an attractive vaccine delivery method for broad-based immunization campaigns.

Original languageEnglish (US)
Article number153
JournalRespiratory research
Volume12
DOIs
StatePublished - Nov 21 2011

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method'. Together they form a unique fingerprint.

Cite this